DuPont Nutrition & Health and Lonza Specialty Ingredients announce an agreement under which the leading biotechnology and specialty ingredient company Lonza will manufacture and supply CARE4U™ 2’-FL – a human milk oligosaccharide (HMOs). This strategic manufacturing collaboration reinforces market confidence in the supply and premium quality of this specialty ingredient.
“By engaging strategically with Lonza, DuPont will be able to accelerate commercialization and offer high-quality HMOs to customers and prospects. The collaboration with Lonza will play a key role in DuPont’s business growth strategy by focusing on providing high-quality consumer health and wellness products,”
said John Rea, Global Business Unit Leader, Cultures, Probiotics, Food Protection, HMO & Fibers, DuPont Nutrition & Health.
“Partnering with DuPont, Lonza will apply its leading science and biotechnology expertise in consumer health and nutrition applications to develop and manufacture superior quality human milk oligosaccharide CARE4U™ 2’-FL,”
said Erasmo Schutzer, President of Lonza’s Consumer Health Division.
Naturally present in human milk, human milk oligosaccharides (HMOs) have been shown to support digestive, immune and cognitive development in infants by modifying the gut microbiota. Infant formula attempts to mimic the nutritional composition of breast milk as closely as possible, and clinical studies have shown that CARE4U™ 2’-FL can mimic some of the health-promoting effects of HMOs. CARE4U™ 2’-FL is produced by microbial fermentation and the final product contains more than 98 percent 2’-fucosyllactose, the most abundant of the more than 130 oligosaccharides in human milk. This makes CARE4U™ 2’-FL one of the purest human milk oligosaccharide products on the market today. Superior powder properties (high purity and density) of CARE4U™ 2’-FL make it easy to use in infant formula and dietary supplements.